untitled
<OAI-PMH schemaLocation=http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd>
<responseDate>2018-01-15T18:33:27Z</responseDate>
<request identifier=oai:HAL:hal-01063911v1 verb=GetRecord metadataPrefix=oai_dc>http://api.archives-ouvertes.fr/oai/hal/</request>
<GetRecord>
<record>
<header>
<identifier>oai:HAL:hal-01063911v1</identifier>
<datestamp>2017-12-21</datestamp>
<setSpec>type:ART</setSpec>
<setSpec>subject:sdv</setSpec>
<setSpec>collection:IRSET</setSpec>
<setSpec>collection:IFR140</setSpec>
<setSpec>collection:HL</setSpec>
<setSpec>collection:CIC</setSpec>
<setSpec>collection:CIC203</setSpec>
<setSpec>collection:UNIV-AG</setSpec>
<setSpec>collection:UNIV-RENNES1</setSpec>
<setSpec>collection:INSERM</setSpec>
<setSpec>collection:IRSET-CCII</setSpec>
<setSpec>collection:IRSET-HIAEC</setSpec>
<setSpec>collection:U835</setSpec>
<setSpec>collection:BIOSIT</setSpec>
<setSpec>collection:UR1-UFR-SVE</setSpec>
<setSpec>collection:STATS-UR1</setSpec>
<setSpec>collection:UR1-HAL</setSpec>
<setSpec>collection:EHESP</setSpec>
<setSpec>collection:USPC</setSpec>
<setSpec>collection:UR1-SDV</setSpec>
<setSpec>collection:IRSET-1</setSpec>
<setSpec>collection:IRSET-2</setSpec>
<setSpec>collection:UNIV-ANGERS</setSpec>
<setSpec>collection:IRSET-EHESP</setSpec>
</header>
<metadata><dc>
<publisher>HAL CCSD</publisher>
<title lang=en>Incidence of Pneumocystis jiroveci Pneumonia among Groups at Risk in HIV-negative Patients</title>
<creator>Fillâtre, Pierre</creator>
<creator>Decaux, Olivier</creator>
<creator>Jouneau, Stéphane</creator>
<creator>Revest, Matthieu</creator>
<creator>Gacouin, Arnaud</creator>
<creator>Robert-Gangneux, Florence</creator>
<creator>Fresnel, Annie</creator>
<creator>Guiguen, Claude</creator>
<creator>Le Tulzo, Yves</creator>
<creator>Jégo, Patrick</creator>
<creator>Tattevin, Pierre</creator>
<contributor>Centre d'Investigation Clinique [Rennes] (CIC) ; Université de Rennes 1 (UR1) - Hôpital Pontchaillou - Institut National de la Santé et de la Recherche Médicale (INSERM)</contributor>
<contributor>Service des maladies infectieuses et réanimation médicale ; Université de Rennes 1 (UR1) - Hôpital Pontchaillou</contributor>
<contributor>Service de médecine interne ; Université de Rennes 1 (UR1) - Hôpital Sud</contributor>
<contributor>Institut de recherche, santé, environnement et travail [Rennes] (Irset) ; Université d'Angers (UA) - Université des Antilles et de la Guyane (UAG) - Université de Rennes 1 (UR1) - École des Hautes Études en Santé Publique [EHESP] (EHESP) - Institut National de la Santé et de la Recherche Médicale (INSERM) - Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )</contributor>
<contributor>Service de pneumologie ; Hôpital Pontchaillou - CHU Pontchaillou [Rennes]</contributor>
<contributor>Service de Parasitologie-Mycologie [Rennes] ; Université de Rennes 1 (UR1) - Hôpital Pontchaillou - CHU Pontchaillou [Rennes]</contributor>
<contributor>Medical Information Department ; CHU Pontchaillou [Rennes]</contributor>
<contributor>Fonction, structure et inactivation d'ARN bactériens ; Université de Rennes 1 (UR1) - Institut National de la Santé et de la Recherche Médicale (INSERM) - Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )</contributor>
<description>International audience</description>
<source>ISSN: 0002-9343</source>
<source>EISSN: 1555-7162</source>
<source>The American Journal of Medicine</source>
<publisher>Elsevier [Commercial Publisher] </publisher>
<identifier>hal-01063911</identifier>
<identifier>https://hal.archives-ouvertes.fr/hal-01063911</identifier>
<identifier>https://hal.archives-ouvertes.fr/hal-01063911/document</identifier>
<identifier>https://hal.archives-ouvertes.fr/hal-01063911/file/1-s2.0-S0002934314005907-main.pdf</identifier>
<source>https://hal.archives-ouvertes.fr/hal-01063911</source>
<source>The American Journal of Medicine, Elsevier [Commercial Publisher] 2014, 12 (127), pp.1242.e11-1242.e17. 〈10.1016/j.amjmed.2014.07.010〉</source>
<identifier>DOI : 10.1016/j.amjmed.2014.07.010</identifier>
<relation>info:eu-repo/semantics/altIdentifier/doi/10.1016/j.amjmed.2014.07.010</relation>
<identifier>PUBMED : 25058862</identifier>
<relation>info:eu-repo/semantics/altIdentifier/pmid/25058862</relation>
<language>en</language>
<subject lang=en>inflammatory diseases</subject>
<subject lang=en>organ transplant</subject>
<subject lang=en>vasculitis</subject>
<subject lang=en>Pneumocystis jiroveci</subject>
<subject lang=en>HIV-negative</subject>
<subject lang=en>hematological malignancy</subject>
<subject>[SDV] Life Sciences [q-bio]</subject>
<type>info:eu-repo/semantics/article</type>
<type>Journal articles</type>
<description lang=en>BACKGROUND: Pneumocystis jiroveci pneumonia in HIV-negative immunocompromised patients is associated with high mortality rates. Although trimethoprim-sulfamethoxazole (TMP-SMX) provides a very effective prophylaxis, pneumocystosis still occurs and may even be emerging, due to sub-optimal characterization of patients most at risk, hence precluding targeted prophylaxis. METHODS: We retrospectively analyzed all cases of documented pneumocystosis in HIV-negative patients admitted in our institution, a referral center in the area, from January 1990 to June 2010, and extracted data on their underlying condition(s). To estimate incidence rates within each condition, we estimated the number of patients followed-up in our area for each condition, by measuring the number of patients admitted with the corresponding international classification diagnostic code, through the national hospital discharge database (PMSI). RESULTS: From 1990 to 2010, 293 cases of pneumocystosis were documented, of whom 154 (52.6%) tested negative for HIV. The main underlying conditions were hematological malignancies (32.5%), solid tumors (18.2%), inflammatory diseases (14.9%), solid organ transplant (12.3%), and vasculitis (9.7%). Estimated incidence rates could be ranked in three categories: i) high risk (incidence rates extgreater 45 cases per 100,000 patient-year): polyarteritis nodosa, granulomatosis with polyangiitis, polymyositis/dermatopolymyositis, acute leukemia, chronic lymphocytic leukemia, and non-Hodgkin lymphoma; ii) intermediate risk (25-45 cases per 100,000 patient-year): Waldenström macroglobulinemia, multiple myeloma, and central nervous system cancer; and iii) low risk ( extless 25 cases per 100,000 patient-year): other solid tumors, inflammatory diseases, and Hodgkin lymphoma. CONCLUSIONS: These estimates may be used as a guide to better target pneumocystosis prophylaxis in the groups most at risk.</description>
<date>2014</date>
</dc>
</metadata>
</record>
</GetRecord>
</OAI-PMH>
